Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

NCT03073200 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

201

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Ixekizumab
DRUG: Placebo
DRUG: Etanercept

Sponsor

Eli Lilly and Company